Advert - Boehringer Ingelheim – AUTH/3462/1/21

Pradaxa Website

For providing a flow diagram for Pradaxa (dabigatran) which directed health professionals to select the most appropriate dose for their patient, taking into account age, concomitant verapamil and bleeding risk, without clearly bringing to their attention that Pradaxa was contraindicated in severe renal impairment, which put patient safety at risk, Boehringer Ingelheim was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical
Clause 7.2 - Providing a misleading diagram
Clause 9.1 - Failing to maintain high standards